The SPOT Project : Motivational Interviewing in Conjunction With Rapid HIV Testing

This study is currently recruiting participants.
Verified August 2013 by Universite du Quebec a Montreal
Sponsor:
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Jessica Caruso, Universite du Quebec a Montreal
ClinicalTrials.gov Identifier:
NCT01931345
First received: August 6, 2013
Last updated: August 22, 2013
Last verified: August 2013
  Purpose

In 2009, a team of researchers from Montreal, Canada, implemented SPOT, an intervention aimed at reducing HIV transmission among men who have sex with men by offering rapid HIV testing in a community setting. During the first phase, counseling based on Quebec guidelines for rapid HIV testing was offered (standard counseling - SC) and in the second phase, counseling based on motivational interviewing (MIC) was developed and validated. The current phase of the project aims to strengthen the work undertaken during previous phases. The objective of the study is to assess the short and medium term effect of MIC on the occurrence of at-risk anal intercourse and its cognitive determinants. Participants will be randomly assigned to either SC or MIC, and will respond to a baseline questionnaire documenting their sexual behavior and psychosexual profile prior to the intervention at the start of their initial visit (T0). The effect of counseling will be assessed following the intervention at the end of the initial visit (T1), at 3 months after the initial visit (T2) and at 6 months after the initial visit (T3).


Condition Intervention
High-risk Sex
Behavioral: Motivational Interviewing Counseling
Behavioral: Standard counseling

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: The SPOT Project: Effect of Counseling Based on Motivational Interviewing Offered in Conjunction With Rapid HIV Testing on the Occurrence of Unprotected Anal Sex and Its Determinants Among Men Who Have Sex With Men (MSM) in Montreal

Resource links provided by NLM:


Further study details as provided by Universite du Quebec a Montreal:

Primary Outcome Measures:
  • Change from baseline occurrence of at-risk anal intercourse at 6 months [ Time Frame: Prior to pre-test counseling at the start of participants' initial visit (baseline, T0), after post-test counseling at the end of the initial visit (T1), at 3 months after the initial visit (T2), and at 6 months after the initial visit (T3) ] [ Designated as safety issue: No ]
    Occurrence of at-risk anal intercourse will be assessed prior to pre-test counseling at the start of participants' initial visit (baseline, T0), after post-test counseling at the end of the initial visit (T1), at 3 months after the initial visit (T2), and at 6 months after the initial visit (T3).


Secondary Outcome Measures:
  • Change from baseline importance that participants accord to taking the necessary steps to protect themselves from HIV at 6 months [ Time Frame: Prior to pre-test counseling at the start of participants' initial visit (baseline, T0), after post-test counseling at the end of the initial visit (T1), at 3 months after the initial visit (T2), and at 6 months after the initial visit (T3) ] [ Designated as safety issue: No ]
    Importance that participants accord to taking the necessary steps to protect themselves from HIV will be assessed prior to pre-test counseling at the start of participants' initial visit (baseline, T0), after post-test counseling at the end of the initial visit (T1), at 3 months after the initial visit (T2), and at 6 months after the initial visit (T3).

  • Change from baseline perceived personal efficacy in protecting themselves from HIV at 6 months [ Time Frame: Prior to pre-test counseling at the start of participants' initial visit (baseline, T0), after post-test counseling at the end of the initial visit (T1), at 3 months after the initial visit (T2), and at 6 months after the initial visit (T3) ] [ Designated as safety issue: No ]
    Perceived personal efficacy in protecting themselves from HIV will be assessed prior to pre-test counseling at the start of participants' initial visit (baseline, T0), after post-test counseling at the end of the initial visit (T1), at 3 months after the initial visit (T2), and at 6 months after the initial visit (T3)

  • Change from baseline intention to protect themselves from HIV at 6 months [ Time Frame: Prior to pre-test counseling at the start of participants' initial visit (baseline, T0), after post-test counseling at the end of the initial visit (T1), at 3 months after the initial visit (T2), and at 6 months after the initial visit (T3) ] [ Designated as safety issue: No ]
    Intention to protect themselves from HIV will be assessed prior to pre-test counseling at the start of participants' initial visit (baseline, T0), after post-test counseling at the end of the initial visit (T1), at 3 months after the initial visit (T2), and at 6 months after the initial visit (T3)

  • Change from baseline extent to which participants have planned to protect themselves from HIV at 6 months [ Time Frame: Prior to pre-test counseling at the start of participants' initial visit (baseline, T0), after post-test counseling at the end of the initial visit (T1), at 3 months after the initial visit (T2), and at 6 months after the initial visit (T3) ] [ Designated as safety issue: No ]
    Extent to which participants have planned to protect themselves from HIV will be assessed prior to pre-test counseling at the start of participants' initial visit (baseline, T0), after post-test counseling at the end of the initial visit (T1), at 3 months after the initial visit (T2), and at 6 months after the initial visit (T3)


Estimated Enrollment: 900
Study Start Date: July 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Motivational Interviewing Counseling
Counseling developed by the research team based on a motivational interviewing approach
Behavioral: Motivational Interviewing Counseling
Counseling developed by the research team based on a motivational interviewing approach
Active Comparator: Standard counseling
Counseling based on Quebec guidelines for rapid HIV testing
Behavioral: Standard counseling
Counseling based on Quebec guidelines for rapid HIV testing

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male
  • 18 years of age or older
  • Resident of Quebec
  • Able to understand French or English
  • Unprotected anal sex with a man on at least one occasion in the last 3 years
  • HIV-negative or HIV status unknown

Exclusion Criteria:

  • Symptoms of fever (over 38°C), headache, muscular pain, fatigue, and/or swollen lymp
  • Previously tested at SPOT
  • Enrolled as a participant in the IPERGAY study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01931345

Contacts
Contact: Thomas Haig, Ph.D. 514-987-3000 ext 3279 haig.thomas@uqam.ca

Locations
Canada, Quebec
SPOT, 1223-A rue Amherst Recruiting
Montreal, Quebec, Canada, H2L 3K9
Contact: SPOT    514-529-7768      
Sponsors and Collaborators
Universite du Quebec a Montreal
Canadian Institutes of Health Research (CIHR)
Investigators
Principal Investigator: Joanne Otis, Ph.D. Université du Québec à Montréal
  More Information

Additional Information:
No publications provided

Responsible Party: Jessica Caruso, Research Agent, Universite du Quebec a Montreal
ClinicalTrials.gov Identifier: NCT01931345     History of Changes
Other Study ID Numbers: SPOT
Study First Received: August 6, 2013
Last Updated: August 22, 2013
Health Authority: Canada: Canadian Institutes of Health Research

Keywords provided by Universite du Quebec a Montreal:
Rapid HIV testing
MSM
Motivational Interviewing
HIV prevention
HIV/AIDS
At-risk anal intercourse
Randomized trial

Additional relevant MeSH terms:
HIV Antibodies
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 14, 2014